Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242  by Pasquato, Antonella et al.
Virology 423 (2012) 14–22
Contents lists available at SciVerse ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r .com/ locate /yv i roEvaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1
protease inhibitor PF-429242
Antonella Pasquato a,1, Cylia Rochat a,1, Dominique J. Burri a, Giulia Pasqual a,
Juan Carlos de la Torre b, Stefan Kunz a,⁎
a Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
b Viral Immunobiology Laboratory, Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, United States⁎ Corresponding author at: Institute of Microbiology,
University of Lausanne, Lausanne CH-1011, Switzerland
E-mail address: Stefan.Kunz@chuv.ch (S. Kunz).
1 Contributed equally to this work.
0042-6822/$ – see front matter © 2011 Elsevier Inc. All
doi:10.1016/j.virol.2011.11.008a b s t r a c ta r t i c l e i n f oArticle history:
Received 21 June 2011
Returned to author for revision 8 August 2011
Accepted 10 November 2011
Available online 10 December 2011
Keywords:
Arenavirus
Glycoprotein
Protease
Anti-viral
InhibitorThe cellular protease subtilisin kexin isozyme-1 (SKI-1)/site-1 protease (S1P) is implicated in the proteolytic
processing of the viral envelope glycoprotein precursor (GPC) of arenaviruses, a step strictly required for pro-
duction of infectious progeny. The small molecule SKI-1/S1P inhibitor PF-429242 was shown to have anti-
viral activity against Old World arenaviruses. Here we extended these studies and show that PF-429242
also inhibits GPC processing and productive infection of New World arenaviruses, making PF-429242 a
broadly active anti-arenaviral drug. In combination therapy, PF-429242 potentiated the anti-viral activity
of ribavirin, indicating a synergism between the two drugs. A hallmark of arenaviruses is their ability to es-
tablish persistent infection in vitro and in vivo. Notably, PF-429242 was able to efﬁciently and rapidly clear
persistent infection by arenaviruses. Interruption of drug treatment did not result in re-emergence of infec-
tion, indicating that PF-429242 treatment leads to virus extinction.
© 2011 Elsevier Inc. All rights reserved.Introduction
Several arenaviruses cause severe viral hemorrhagic fevers (VHF)
in humans and represent a serious public health problem in their en-
demic regions (Geisbert and Jahrling, 2004). The Old World (OW) ar-
enavirus Lassa virus (LASV) in West Africa causes several hundred
thousand infections per year (McCormick and Fisher-Hoch, 2002)
and the New World (NW) arenaviruses Junin (JUNV), Machupo
(MACV), Guanarito (GTOV), and Sabia virus (SABV) have emerged
as etiological agents of severe VHF in the Americas (Buchmeier et
al., 2007). The worldwide distributed prototypic arenavirus lympho-
cytic choriomeningitis virus (LCMV) is a neglected human pathogen
of clinical signiﬁcance (Barton et al., 2002). New arenaviruses emerge
on average every three years as illustrated by the recent discoveries of
Chapare virus and Lujo virus that were associated with fatal hemor-
rhagic fever cases in Bolivia and Southern Africa, respectively
(Briese et al., 2009; Delgado et al., 2008). A predictive factor for fatal-
ity in arenavirus VHF is the viral load, suggesting competition be-
tween viral multiplication and the host's anti-viral immune defense
(McCormick and Fisher-Hoch, 2002). Drugs targeting different steps
in the arenavirus life cycle may limit viral replication and spread, pro-
viding the infected host with a window of opportunity to develop anUniversity Hospital Center and
. Fax: +41 21 314 4060.
rights reserved.anti-viral immune response able to control, and ultimately eliminate
the virus.
Arenaviruses are enveloped viruses with a bisegmented negative
strand RNA genome and a non-lytic life cycle restricted to the cell cy-
toplasm (Buchmeier et al., 2007). Each genomic RNA segment L (ca
7.3 kb) and S (ca 3.5 kb) contains two open reading frames that direct
production of viral polypeptides in opposite orientation. The S RNA
encodes the viral glycoprotein precursor, GPC, and the nucleoprotein,
NP, whereas the L RNA encodes the viral RNA-dependent RNA poly-
merase (L), and a small RING ﬁnger protein Z. The GPC precursor is
initially synthesized as a single polypeptide (ca 75 kDa) that is pro-
cessed post-translationally by the cellular proprotein convertase
(PC) subtilisin kexin isozyme-1 (SKI-1)/site-1 protease (S1P), yield-
ing GP1 (40–46 kDa) and GP2 (35 kDa) (Beyer et al., 2003; Kunz et
al., 2003; Lenz et al., 2001; Rojek et al., 2008a). The GP1 portion serves
as viral attachment via interaction with cellular receptors. The trans-
membrane GP2 resembles the fusion-active membrane-proximal
parts of other enveloped viruses and is involved in fusion of the
viral membrane with cellular membranes (Eschli et al., 2006).
The current therapy for treatment of human arenavirus infection
is an off-labeled use of the nucleoside analogue ribavirin (Rib) (1-β-
D-ribofuranosyl-1,2,4-triazole-3-carboxamide) (Parker, 2005). Early
administration of Rib reduces both morbidity and mortality in
humans infected with LASV (McCormick et al., 1986), and experimen-
tal infections with MACV (Kilgore et al., 1995) and JUNV
(Weissenbacher et al., 1987) in animals. However, for its highest efﬁ-
cacy Rib needs to be administered intravenously and early infection.
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important to develop novel anti-arenaviral drugs that could be used
individually or in combination therapy to combat human pathogenic
arenaviruses.
Processing of arenavirus GPC by SKI-1/S1P is crucial for infectious
virus production and cell-to-cell propagation of the virus (Beyer et al.,
2003; Kunz et al., 2003; Lenz et al., 2001; Rojek et al., 2008a). In the
host, SKI-1/S1P is implicated in the regulation of lipid metabolism
through the processing of sterol regulatory element-binding proteins
(SREBP-1 and SREBP-2), (Brown and Goldstein, 1997; Sakai et al.,
1998). Another cellular substrate of SKI-1/S1P is the activating tran-
scription 6 (ATF6), which is a key player in the cellular response to
ER stress (Ye et al., 2000). In recent studies, SKI-1/S1P-adapted ser-
pins (Maisa et al., 2009) and peptide-based small molecule suicide in-
hibitors of SKI-1/S1P (Rojek et al., 2010) efﬁciently inhibited
productive arenavirus infection. However, the inhibitors used in
these proof-of-principle studies face severe limitations for their use
as anti-viral drugs in vivo. Small molecule drug screens conducted
by Pﬁzer Inc. discovered a novel speciﬁc SKI-1/S1P inhibitor, the
amino-pyrrolidine amide compound PF-429242 (Hawkins et al.,
2008; Hay et al., 2007). PF-429242 efﬁciently blocked SKI-1/S1P-me-
diated processing and subsequent activation of SREBP2 in cell culture
and a small animal model (Hawkins et al., 2008). The toxicity proﬁle
and pharmacokinetic properties made PF-429242 a promising candi-
date for a novel anti-arenaviral drug. PF-429242 was able to block the
biosynthesis of fusion-active mature GPC of the OW arenaviruses
LCMV and LASV and showed potent anti-viral activity against LCMV
and LASV in acute infection in cultured cells (Urata et al., 2011).
These ﬁndings suggested the feasibility of using PF-429242 as a
novel anti-arenaviral drug. Here we extended these studies and
show that PF-429242 is a broadly active anti-arenaviral drug that
acts in synergy with ribavirin. Moreover, PF-429242 efﬁciently and
rapidly cleared persistent virus from infected cells. Interruption of
drug treatment did not result in re-emergence of infection, indicating
that PF-429242 treatment resulted in virus extinction.Fig. 1. The inhibitor PF-429242 blocks SKI-1/S1P-mediated processing of SREBP2 and ATF6, b
tion of the heat shock 70 kDa protein 5 (HSPA5) and the SREBP2-mediated upregulation of
seeded in a 12-well plate and cultured overnight. To induce genes downstream of ATF6 c
were induced by treating cells with 50 μM mevastatin (Mev) for 18 h. At 14 h after ad
(10 μM) or DMSO vehicle were added to the cells. At 4 h post-treatment, cells were washe
Materials and methods section. Data were normalized using the calibrator gene hydroxym
mock (DMSO)-treated cells (means±SD; n=3). (B) PF-429242 has no effect on SKI-1/S1P
SKI-1/S1P containing a C-terminal V5-tag. Four hours post transfection, the indicated conc
cells were lysed, total protein separated by SDS-PAGE and blotted to nitrocellulose. Blots w
ECL for detection. The positions of full-length SKI-1/S1P (A), the form processed at the B/B
the degree of autoprocessing, blots were subjected to densitometric analysis (Kunz et al., 2
to the precursor (A).Results
Effects of PF-429242 on SKI-1/S1P-mediated processing of SREBP2, ATF6,
and SKI-1/S1P autoprocessing
The SKI-1/S1P inhibitor PF-429242 was originally identiﬁed in a
high-throughput small molecule screen and has been shown to efﬁ-
ciently block SKI-1/S1P-mediated cleavage of the cellular substrate
SREBP2 in vitro and in vivo (Hawkins et al., 2008; Hay et al., 2007).
To further characterize the activity of PF-429242 against cellular tar-
gets, we tested the ability of PF-429242 to inhibit the processing of
the activating transcription factor ATF6 in response to ER stress. To
this end, we studied the effect of PF-429242 on the ATF6-mediated
induction of the heat shock 70 kDa protein 5 (HSPA5) triggered by
ER stress and SREBP2-mediated upregulation of the 3-hydroxy-3-
methylglutaryl-Coenzyme A synthase (HMGCS1) upon sterol deple-
tion, respectively. To induce ER stress, we treated CHOK1 cells with
tunicamycin, an inhibitor of protein N-glycosylation, for 4 h. For sterol
depletion, we treated cells with mevastatin, and inhibitor of choles-
terol biosynthesis, for 18 h. Upon ER stress induction and sterol de-
pletion, cells were lysed, total RNA extracted, and mRNA levels for
HSPA5 and HMGCS1 assessed by quantitative real-time PCR (RT-
qPCR). Treatment of cells with 10 μM PF-429242 signiﬁcantly blocked
induction of both HSPA5 and HMGCS1, indicating efﬁcient blocking of
SKI-1/S1P-mediated cleavage of ATF6 upon ER stress and SREBP2 in-
duced by cholesterol depletion (Fig. 1A).
During biosynthesis, SKI-1/S1P undergoes maturation that in-
volves proteolytic cleavage at three processing sites (A, B, B′, and C)
to generate the active form of the enzyme (Elagoz et al., 2002;
Toure et al., 2000). A previously described suicide peptide inhibitor
of SKI-1/S1P derived from the C processing site, dec-RRLL-CMK, efﬁ-
ciently blocked processing of cellular and viral substrates (Pasquato
et al., 2006; Rojek et al., 2010). Since the peptide substrate used for
the small molecule screen that identiﬁed PF-429242, Ac-VFRSLK-
MCA, contained the SKI-1/S1P B site consensus sequence RSLKut not SKI-1/S1P autoprocessing. (A) Effect of PF-429242 on the ATF6-mediated induc-
the 3-hydroxy-3-methylglutaryl-Coenzyme A synthase (HMGCS1). CHOK1 cells were
ells were treated with 5 μg/ml tunicamycin (TN) for 4 h. Genes downstream SREBP2
dition of mevastatin and at the same time with tunicamycin treatment, PF-429242
d twice with PBS and total RNA isolated to perform RT-qPCR analyses as described in
ethylbilane synthase (HMBS). Data are presented as fold-induction above levels for
autoprocessing. SKI-1/S1P-deﬁcient SRD12B cells were transfected with recombinant
entrations of PF-429242 were added and left throughout the experiment. After 48 h,
ere probed with an anti-V5 antibody using a HRP-conjugated secondary antibody and
′ site and the C site are indicated. Tubulin was included as a loading control. To assess
003) and the signal of the band corresponding to the mature enzyme (C) normalized
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S1P autoprocessing. For this purpose, we transiently expressed re-
combinant SKI-1/S1P bearing a C-terminal V5-tag in SKI-1/S1P deﬁ-
cient SRD12B cells (Rawson et al., 1998). Autoprocessing of SKI-1/
S1P at the B/B′ site, followed by the C site, results in a characteristic
pattern of bands that represents the uncleaved precursor, the inter-
mediate form, and the mature protein (Fig. 1B). SKI-1/S1P autopro-
cessing was not affected by treatment with up to 100 μM of PF-
429242 (Fig. 1B), a concentration well above the one sufﬁcient to
block processing of ATF6 and SREBP2 (Fig. 1A). Together, these data
showed that PF-429242 blocks SKI-1/S1P-mediated processing of
SREBP2 and ATF6, but not SKI-1/S1P autoprocessing, thus revealing
important differences between SKI-1/S1P-mediated processing ofFig. 2. The SKI-1/S1P inhibitor PF-429242 differentially inhibits processing of a broad range o
GTOV. HEK293 cells and CHOK1 cells were transiently transfected with expression plasmids
tamine. Controls (C) were transfected with empty vector only. At 4 h post transfection, the m
containing 10 μM PF-429242 (+) or DMSO vehicle (−). After 48 h cells were lysed and tot
branes tubulin (Tub) was revealed with a mAb anti-α-tubulin. The positions of GPC and G
and exposed at different times. UB indicates an unspeciﬁc band detected in CHOK1 cells. (
cell lines stable expressing MLV Gag and Pol were co-transfected with the MLV genomic
(JUN), MACV (MAC), TACV (TAC), GTOV (GTO), AMPV (AMP), and VSV G protein (VSV). Fo
conditioned supernatants were harvested and cleared. Serial dilutions were prepared and
GFP using a rabbit anti-GFP antibody and a FITC-labeled secondary antibody (means±SD
cells. A549 cells were seeded in a white 96-well clear bottom plates and cultured overnigh
429242. After 48 h, cell viability was assessed using CellTiter-GloR luminescent cell viabili
LB 941. Values were normalized against the controls (DMSO vehicle) (means±SD; n=3)
A549 cells in LabTek tissue culture chambers were pre-treated with the indicated concent
LCMV ARM53b, and rLCMV-RRRR (MOI=0.01). After 16 h in presence of the inhibitor, cul
and mAb 113 to LCMVNP (means±SD; n=3). (E) The inhibitor PF-429242 reduces cell-
LCMV ARM53b, and rLCMV-RRRR (MOI=0.01). One hour post-infection, the indicated con
48 h, cells were detached by mild trypsinization, ﬁxed, and intracellular staining for NP perf
and methods section). The percentage of NP positive cells is given (means±SD; n=3). (E)
ARM53b, and rLCMV-RRRR (MOI=3) and PF-429242 (25 μM) added at one hour post infec
hibitor, and infectious virus titers determined by IFA on VeroE6 cells (means±SD; n=3).the cellular substrates ATF6 and SREBP2 on the one hand and autop-
rocessing at the B/B′ and C site on the other hand.
Effect of PF-429242 on SKI/S1P-mediated processing of a broad range of
arenavirus GPCs
PF-429242 potently inhibited processing of the GPCs of the OW
arenaviruses LASV and LCMV (Urata et al., 2011). The GPC processing
sites of OW arenaviruses resemble the sequence RRLL ↓ of the SKI-1/
S1P C autoprocessing site, whereas the recognition sequences found
in NW arenaviruses are strikingly different with those of the NW
Clade B viruses JUNV, TACV, and MACV resembling the B autoproces-
sing site RT/SLK ↓ (Pasquato et al., 2011). This led us to ﬁrst assess thef arenavirus GPCs. (A) PF-429242 blocks proteolytic processing of the GPCs of JUNV and
for LASV GPC and JUNV GPC and LASV GPC and GTOV GPC, respectively using Lipofec-
ediumwas removed and replaced by fresh medium supplemented with cholesterol and
al protein probed with mAb M2 (anti-FLAG) in Western blot. After stripping of mem-
P2 are indicated. For optimal detection of GPC and processed GP2, blots have been cut
B) PF-429242 blocks the expression of functional arenavirus GPCs. GP2293 packaging
plasmid pLZRS-Luc-gfp, and expression plasmids for the GPCs of LASV (LAS), JUNV
ur hours post-transfection, 25 μM PF-429242 or DMSO vehicle were added. After 48 h
added to VeroE6 monolayers. Infection was detected immunoﬂuorescence staining for
; n=3). Note that the y-axis has a log scale. (C) Cytotoxicity of PF-429242 in A549
t, resulting in monolayers. Cells were treated with the indicated concentrations of PF-
ty assay and luminescence measured using a Berthold Multimode Plate reader TriStar
. (D) PF-429242 has no effect on early infection with LCMV and JUNV: Monolayers of
rations of PF-429242 for one hour and then infected with 200 PFU of JUNV Candid 1,
tures were ﬁxed and foci of infected cells detected by IF using mAb BG12 to JUNV NP
to-cell propagation of infection: Monolayers of A549 cells were infected with JUNV,
centrations of PF-429242 were added and cells cultured in presence of inhibitor. After
ormed, followed by quantiﬁcation of NP positive cells by ﬂow cytometry (see Materials
PF-429242 reduces virus production: A549 monolayers were infected with JUNV, LCMV
tion. Cell culture supernatants were harvested, dialyzed against HBSS to remove the in-
Fig. 3. Inhibition of replication of LCMV variants by ribavirin (Rib). (A) Growth of
LCMVs: A549 cells were infected with wild-type LCMV ARM53b, LCMV cl-13, rLCMV-
RRRR, rLCMV-VSVG, and JUNV (MOI=0.1) and virus titers determined in the superna-
tants after the indicated time points by plaque assay on VeroE6 cells. (B) Inhibition of
replication of LCMV variants by Rib. A549 cells were seeded in a 96-well plate and cul-
tured overnight, resulting in monolayers. Cells were infected with LCMV-ARM53b,
LCMV cl-13, rLCMV-RRRR, rLCMV-VSVG, and JUNV at MOI=0.01. At 45 min post infec-
tion (p.i.), inoculums were removed and replaced by fresh medium containing increas-
ing concentrations of Rib (25–500 μM). At 48 h p.i., cells were ﬁxed and infection
evaluated by IFA using mAb 113 to LCMV NP and mAb BG12 to JUNV NP. Cell nuclei
were counterstained, 100 cells examined and NP positive cells scored. Each value is
the mean of two independent experiments. Values were normalized against the con-
trols (without drug).
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GPCs of selected NW arenaviruses. For these studies, we chose
JUNV, the most important pathogenic arenavirus in the Americas,
and GTOV that is also highly pathogenic. Brieﬂy, we transfected
CHOK1 cells with expression plasmids for GPC of LASV, JUNV, and
GTOV containing a C-terminal FLAG tag followed by addition of PF-
429242. Because the effects of PF-429242 on cell cholesterol metabo-
lism (Hawkins et al., 2008), we supplemented with cholesterol the
media of PF-429242 treated cells (Rawson et al., 1998; Rojek et al.,
2010). After 48 h, cells were lysed and total protein probed in
Western-blot with monoclonal antibody (mAb) M2 anti-FLAG. PF-
429242 reduced proteolytic processing of LASV GPC as well as the
GPCs of JUNV and GTOV (Fig. 2A).
To complement these studies, we examined the ability of PF-
429242 to inhibit the biosynthesis of functional arenavirus GP using
GP-mediated cell entry as a functional readout. For this purpose, we
proﬁted from the fact that recombinant retroviruses can be pseudo-
typed with the GPCs of arenaviruses (Reignier et al., 2006; Rojek et
al., 2006). Since host cell attachment and entry of arenaviruses is me-
diated exclusively by the viral envelope GP, retroviral pseudotypes
are suitable to test correct processing and the biological function of
arenavirus GPs. Recombinant Moloney leukemia virus (MLV) contain-
ing a green ﬂuorescence protein (GFP) reporter gene was pseudo-
typed with GPCs of LASV, JUNV, MACV, Tacaribe virus (TACV),
GTOV, and Amapari virus (AMPV) by co-transfection of a HEK293
packaging cell line stable expressing MLV Gag and Pol with plasmids
containing the retroviral genome and the viral glycoprotein provided
in trans (Rojek et al., 2006). As a control, we included MLV pseudo-
types bearing the G protein of vesicular stomatitis virus (VSV),
which is structurally unrelated to arenavirus GPC and does not re-
quire processing for fusion activity (Lyles and Rupprecht, 2007). To
assess the impact of PF-429242 on the expression of functional viral
GPs, co-transfected packaging cells were exposed to the drug at 4 h
post-transfection. After 48 h in presence of drug, the pseudotypes
were harvested and titers determined by infection of fresh mono-
layers of Vero E6 cells, followed by detection of GFP expressing cells
in ﬂuorescence microscopy. As expected, treatment of cells with
30 μM PF-429242 reduced the production of infectious LASV pseudo-
types by circa 3 logs (Fig. 2B). Production of pseudotypes of JUNV,
MACV, GTOV, and AMPV was diminished by circa 2 logs and titers
of TACV pseudotypes were reduced by circa 1 log. The drug did not af-
fect the titers of VSV pseudotypes, excluding a negative impact on the
production and/or assembly of the retroviral core (Fig. 2B). Our data
suggest that PF-429242 affects processing and/or incorporation of ar-
enavirus GPCs with LASV>JUNV>TACV (Fig. 2B).
To validate the anti-viral effect of PF-429242 against the NW are-
naviruses in the context of productive arenavirus infection, we used
the attenuated JUNV vaccine strain Candid 1 whose GPC processing
was shown to be mediated by SKI-1/S1P (Rojek et al., 2008a). As
cell culture model for our study, we employed the human lung epi-
thelial cell line A459. Our choice was based on the evidence that
human pathogenic arenaviruses frequently enter the human body as
infectious aerosols and that the lung is one of the major target
organ of arenaviruses in humans and animal models (Kenyon et al.,
1992). To exclude unspeciﬁc cell toxicity of PF-429242, A549 cells
were treated with increasing concentration of PF-429242 and cell vi-
ability assessed after 48 h by Cell Titer Glo® assay which determines
cellular levels of ATP. Treatment with up to 50 μM PF-429242 did not
cause detectable cytotoxicity (Fig. 2C). First, we addressed possible
effects of PF-429242 on early steps of JUNV infection. For this we
infected cells at low (0.01) MOI with JUNV Candid 1 and LCMV-WT.
As a control, we used a recombinant LCMV, rLCMV-RRRR in which
the SKI-1/S1P recognition site of GPC had been substituted by a ca-
nonical furin recognition site (RRRR). As a consequence, GPC proces-
sing of rLCMV-RRRR is independent of SKI-1/S1P, but dependent on
cellular furin (Rojek et al., 2010). PF-429242 was added 1 h prior toinfection and cultures ﬁxed at 16 h p.i. Numbers of infected foci
were determined by immunoﬂuorescence (IF) staining for the viral
nucleoproteins (NP). PF-429242 had no signiﬁcant effect on the num-
ber of infected foci, making inhibition of viral entry and/or other early
steps of the viral life cycle rather unlikely (Fig. 2D). To assess inhibi-
tion of cell-to-cell propagation of infection, we infected cells at low
(0.01) MOI and added increasing concentrations of PF-429242 at 1 h
post-infection. Cells were cultured for 48 h and the percentage of
infected cells determined by intracellular staining for viral NPs. In-
creasing concentrations of PF-429242 resulted in a marked dose-
dependent reduction in NP positive cell numbers in cultures infected
with JUNV and LCMV, whereas cells infected with rLCMV-RRRR
showed only a slight reduction at higher drug concentrations
(Fig. 2E). A similar effect of the SKI-1/S1P inhibitor dec-RRLL-CMK
on rLCMV-RRRR has been reported earlier (Rojek et al., 2010), likely
due to a role of SKI-1/S1P in the multiplication of rLCMV-RRRR unre-
lated to GPC processing. Next, we assessed the ability of PF-429242 to
block virus production from infected cells. For this purpose, A549
cells were infected at high (3) MOI and virus production determined
in presence and absence of PF-429242. Treatment with the inhibitor
at 25 μM resulted in a marked reduction of titers in cultures infected
with JUNV and LCMV, whereas the titers of rLCMV-RRRR were only
mildly reduced (Fig. 2F). In sum, these data showed that PF-429242
is broadly active against Old World and New World arenaviruses.
However signiﬁcant quantitative differences exist in the ability of
PF-429242 to block GPC processing of OW versus NW arenaviruses.
These ﬁndings are in line with our previous observation of a differen-
tial recognition of Old World and NewWorld arenavirus GPCs by SKI-
1/S1P (Pasquato et al., 2011).
PF-429242 and ribavirin show synergistic anti-viral effects
In vitro and in vivo studies have documented the prophylactic and
therapeutic value of Rib against several arenaviruses. To investigate
the combinatorial effects of PF-429242 and Rib on arenavirus multi-
plication we employed the prototypic arenavirus LCMV and JUNV
Candid 1. To control for the target speciﬁcity of PF-429242 drug ac-
tion, we included the furin-dependent rLCMV-RRRR. As an additional
18 A. Pasquato et al. / Virology 423 (2012) 14–22control, we included a recombinant LCMV expressing the G protein of
vesicular stomatitis virus (VSV) (rLCMV-VSVG), which does not re-
quire proteolytic processing (Pinschewer et al., 2003). LCMV and
rLCMV-RRRR exhibited similar growth curves in A549 cells, whereas,
JUNV and rLCMV-VSVG grew to lower titers (Fig. 3A). Both LCMV and
rLCMV-VSVG showed similar sensitivities toward Rib, whereas
rLCMV-RRRR and JUNV showed consistently a somewhat lower sensi-
tivity to the drug (Fig. 3B).
Next, we determined the cytotoxicity of Rib and PF-429242 indi-
vidually as well as combinations thereof in A549 cells. Cells were trea-
ted with increasing concentration of Rib (25 μM–500 μM) and cell
viability was assessed after 48 h by Cell Titer Glo® assay. A549 cells
tolerated Rib up to 500 μM without signiﬁcant drop in viability
(Fig. 4A). Treatment with the highest dose of Rib and PF-429242 con-
centrations we planned to use, alone or in combination, did not cause
signiﬁcant cytotoxicity during a 48 h treatment (Fig. 4B).
To study anti-viral effects of combinations of Rib and PF-429242,
A549 cells were infected with LCMV, rLCMV-RRRR, and JUNV. Infec-
tion at low MOI (0.01) was followed by treatment with increasing
concentrations of PF-429242 (0–30 μM), either alone or in combina-
tion with 25 μM Rib, which by itself resulted in only partial inhibition
of viral infection. To assess anti-viral activity of the drug combina-
tions, we detected viral infection at 48 h post infection. For this pur-
pose, we detected the viral NP in cells by intracellular staining with
mAb 113 and determined the percentage of infected cells by ﬂow
cytometry. This readout allows an accurate determination of cell-to-
cell propagation of virus in cells under drug treatment. Combination
of PF-429242 with Rib resulted in a markedly stronger anti-viral ef-
fect (Fig. 4C). To distinguish a simple additive effect of PF-429242
with Rib from a synergistic effect, or potential interference between
the two drugs, we normalized the infection in Rib-treated and
untreated cells (100% infection in absence of PF-429242) and plottedFig. 4. Combined anti-viral effects of PF-429242 and Rib. (A, B) Cytotoxicity of the combinat
indicated concentrations of Rib and PF-429242 (PF). After 48 h, cell viability was assessed u
controls (DMSO vehicle) (means±SD; n=3). (C) Treatment of infected cells with Rib and
moval of unbound virus, fresh medium was added containing the indicated concentrations o
were detached, single cell suspensions prepared, and viral NP detected by intracellular stain
cells (PBS, PF-429242=0) as 100%. Each point represents the average of two independent ex
infection in cells not treated with PF-429242 (0) of each series (Rib, PBS) was set to 100%.
lapping curves as e.g. seen in case of rLCMV-RRRR that is not affected by PF-429242.the data in function of increasing concentration of PF-429242
(Fig. 4D). A simple additive effect of the drugs would result in over-
lapping dose-response curves for PF-429242 in presence and absence
of Rib. We observed a greater than additive effect between PF-429242
and Rib in cells infected with LCMV and JUNV, but not the SKI-1/S1P-
independent rLCMV-RRRR (Fig. 4D). Together the data indicated that
the simultaneous targeting of viral replication (Rib) and GPC proces-
sing (PF-429242) have a synergistic inhibitory effect on arenavirus
multiplication and cell-to-cell spread.
Effect of PF-429242 on arenavirus persistently infected cells
Previous studies on LCMV infection in vitro and in vivo revealed
that expression of the viral NP and GPC is differently regulated during
acute and persistent infections (Oldstone and Buchmeier, 1982). NP
expression levels remained high and relatively constant during the
acute and persistent phases of LCMV infection. In contrast, GPC was
highly expressed during the ﬁrst days of acute infection, followed
by a marked down-regulation during the transition to persistent in-
fection. We reasoned that low expression levels of GP in persistently
infected cells could facilitate the antiviral effect of PF-429242 mediat-
ed targeting of GPC processing during arenavirus persistence. To ex-
amine this hypothesis we infected A549 cells with LCMV and the
expression of GPC and NP monitored over time. Consistent with pre-
vious studies, we observed a dramatic down-regulation of GPC, but
not NP after 72 h of infection (Fig. 5A). After serial passages of
LCMV-infected A549 cells for 4 weeks >98% of cells expressed NP as
assessed by intracellular immunostaining and ﬂow cytometry,
whereas GPC was barely detectable (data not shown).
To assess the activity of PF-429242 against persistent virus, persis-
tently infected cells were plated and after attachment exposed to PF-
429242, Rib, and the combination of PF-429242 and Rib. Cells wereion of Rib and PF-429242 in A549 cells. Monolayers of A549 cells were treated with the
sing CellTiter-Glo® cell viability assay as in Fig. 2C. Values were normalized against the
PF-429242. A549 cells were infected with the indicated viruses at MOI=0.01. After re-
f PF-429242 either alone (PBS) or in combination with 25 μM Rib (Rib). After 48 h, cells
ing as in 2E. Infection was normalized setting the percentage of infection in untreated
periments. (D) Data shown in (C) with normalization for each series: the percentage of
A simple additive effect of PF-429242 and Rib on virus infection would result in over-
Fig. 5. Potent anti-viral effect of PF-429242 in persistently infected cells. (A) Differential regulation of LCMV NP and GP expression during acute infection. A549 cells were infected
with LCMV (MOI=0.1). At the indicated time points post infection (p.i.), cells were lysed in SDS-PAGE sample buffer, protein separated and probed in Western-blot using mono-
clonal antibody (mAb) 83.6 to LCMV GP2 (GP2), polyclonal guinea pig serum to LCMV NP (NP), and a mAb to α-tubulin (α-Tu), combined with HRP-conjugated secondary anti-
bodies and enhanced chemiluminescence (ECL) as described (Rojek et al., 2007a). Alpha-tubulin (α-Tu) was used as loading control. The unprocessed GPC and mature GP2 are
indicated. (B) PF-429242 prevents infectious virus production from persistently infected cells. A549 cells were persistently infected with LCMV cl-13 for 4 weeks. Cells were plated
and either mock treated (PBS, DMSO), treated with 25 μM Rib (Rib), 10 μM PF-429242 (PF-429242), and a combination of 25 μM Rib and 10 μM PF-429242 (PF-429242+Rib). Cells
were treated with drugs for 15 days. On day 15, drugs were removed and cells cultured in drug-free medium. At the indicated time points, cell culture supernatant was removed and
cells passed. Virus titers were determined in cell culture supernatants by IFA on fresh monolayers of A549 cells. Each time value represents the average of two independent exper-
iments. (C) Detection of viral RNA in persistently infected cells treated with PF-429242 and Rib. Persistently infected A549 cells were treated with PF-429242 and Rib as in (B). At
the indicated time points, cells were passed. Half of the cells were subjected to RNA extraction, followed by detection of viral RNA by RT-qPCR as described in Materials and methods
section. Data were normalized using the calibrator gene GAPDH. The resulting values for viral RNA load were then normalized to the signal obtained from uninfected cells (u)
(means±SD; n=3). (D) Detection of LCMV GPC mRNA in cells at 4, 7, 11, and 14 days after stop of PF-429242 treatment. Cellular RNA was isolated, subjected to reverse transcrip-
tion, and a 1000 bp fragment of GPC containing the SKI-1/S1P recognition site ampliﬁed by PCR as detailed in Materials and methods section. As controls, RNA from control cells
(DMSO treated) on day 2 of infection (Control), as well as the plasmid pC-GPC containing the LCMV GPC open reading frame were used. The position of the expected band for
LCMV GPC is indicated with an arrow. (E) Representative examples of sequence analysis including chromatograms of the GPC region containing the SKI-1/S1P cleavage site in
PCR products obtained in (D). The consensus sequence of LCMV GPC is given at the top and the SKI-1/S1P processing site (RRLA) is underlined. The sequences of four out of 10
PCR products are shown. Please note that only wild-type sequences were detected.
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were removed and cells passed for another 11 days in drug-free me-
dium. The anti-viral effect of drug combinations was assessed in
two ways 1) determination of infectious virus titers in cell culture su-
pernatants from infected cells in presence and absence of drugs and
2) detection of viral RNA in treated and untreated cells. To monitor
infectious virus production from persistently infected cells over
time, samples of cell culture supernatant were taken at the indicated
time points. Serial dilutions were added to fresh monolayers of A549
cells and virus titers determined by immunofocus assay (IFA). Treat-
ment with Rib at 25 μM had no signiﬁcant effect on infectious virus ti-
ters over time (Fig. 5B). In contrast, treatment with PF-429242 alone
resulted in a dramatic reduction of infectious virus titers to undetect-
able levels after 5 days of treatment (Fig. 5B). In contrast to results
observed during acute infection (Fig. 4), the combination of PF-
429242 with Rib did not result in an enhanced anti-viral effect
(Fig. 5B), indicating that PF-429242 was the major active componentof the drug combination. After removal of drugs, we monitored re-
emergence of infectious virus, but were unable to detect infectious
particles in the supernatants of cells treated with PF-429242 or the
combination of PF-429242 and Rib (Fig. 5B).
Because the limited sensitivity of the IFA used to monitor produc-
tion of infectious progeny with a cut-off of circa 100 PFU/ml, we used
also real-time quantitative PCR (RT-qPCR) to detect viral RNA in cells,
using the house keeping gene GAPDH for normalization (Materials
and methods section). Treatment of persistently infected cells with
PF-429242 resulted in progressive reduction of viral RNA levels over
the time of treatment by circa 3 logs. After removal of drug, cellular
viral RNA levels remained 4–5 logs lower than in untreated control
cells, reaching background levels on day 7 after stopping the treat-
ment (Fig. 5C).
In order to detect possible viral escape variants, we sought to am-
plify mRNA of the viral GPC present in cells on days 4, 7, 11, and 14
after removal of the drug. Using classical PCR with a set of speciﬁc
20 A. Pasquato et al. / Virology 423 (2012) 14–22primers for GPC, we were able to detect low levels of GPC mRNA in
cells on day 4 after removal of the drug, but not at later time points
(Fig. 5D). Sequencing of the GPC open reading frame from the ampli-
ﬁed GPC fragment from cells on day 4 after drug removal did not re-
veal point mutations in the SKI-1/S1P processing sites (Fig. 5E). In
addition, several attempts to isolate infectious virus at this or later
time points failed. Together, the data suggest that treatment of persis-
tently infected cells with PF-429242 not only reduced infectious virus
production, but also led to virus extinction.
Discussion
Previous studies showed efﬁcient inhibition of LASV and LCMV
GPC cleavage by PF-429242 (Urata et al., 2011), however, its activity
against processing of NW arenavirus GPC was unknown. Using a
panel of recombinant NW arenavirus GPCs, we found that PF-
429242 differentially inhibited processing of GPCs derived from are-
naviruses belonging to different phylogenetic groups. When com-
pared to its activity against SKI-1/S1P-mediated cleavage of OW
arenavirus GPCs, PF-429242 seemed overall less active against NW
virus GPC processing. Anti-viral activity of PF-429242 against NW
arenaviruses was validated using the JUNV vaccine strain Candid1
as a model. PF-429242 showed potent anti-viral activity preventing
cell-to-cell propagation of virus and production of infectious progeny
virus from infected cells. While IC50 values for LCMV were in the
range of 2 μM, IC50 for JUNV was around 5 μM.
The differential inhibition of SKI-1/S1P-mediated processing of
OW and NW arenavirus GPCs suggests that PF-924292 blocks SKI-1/
S1P in a substrate-dependent manner. The basis of this substrate-
dependence of inhibition is currently unknown, but may involve per-
turbation of molecular interactions between SKI-1/S1P catalytic pock-
et and different substrates amino acids other than those that are
included in the RX(hydrophobic)X consensus motif. Indeed, previous
studies showed the importance of residues N-terminal of the SKI-1/
S1P recognition site for optimal processing of peptides derived from
some viral substrates but not others (Pasquato et al., 2011; Pasquato
et al., 2006).
Initial evaluation of PF-429242 in vivo in a small animal model
raised concerns about the possible application of PF-429242 in the
context of chronic diseases, such as familial hypercholesterolemia
(Hawkins et al., 2008). In contrast, human pathogenic arenaviruses
cause acute diseases, limiting anti-viral treatment to a time window
of a few weeks. Considering these relatively short periods of treat-
ment, the toxicological and pharmacokinetics proﬁle of PF-429242
makes it a promising anti-arenaviral drug candidate (Hawkins et al.,
2008). To further evaluate the anti-viral potential of PF-429242, we
tested its efﬁcacy in combination with Rib, and found that the combi-
nation of PF-429242 with Rib revealed stronger than additive effect of
the two drugs. The basis for this apparent synergism is currently
unclear, but may lie in the distinct underlying anti-viral mechanisms
of the two drugs. Rib inhibits arenavirus infection at the level of rep-
lication (Ruiz-Jarabo et al., 2003) and can also act as a mutagen
(Moreno et al., 2011), whereas PF-429242 acts on the biosynthesis
of the viral GP, blocking the formation of infectious progeny virus
from infected cells. The synergistic effect of the combination of Rib
with PF-4289242 suggests that the potency of the SKI-1/S1P inhibitor
in infected cells may depend on the absolute expression levels of the
drug target, the viral GPC.
A hallmark of arenaviruses is their ability to establish chronic per-
sistent infections in permissive animal cells (Oldstone, 2002). The
transition from acute to persistent infection is characterized by a
marked down-regulation of the viral GPC in vitro and in vivo
(Oldstone and Buchmeier, 1982). The resulting low expression levels
of GPC likely become a limiting factor for infectious virus production
and may represent an “Achilles heel” for persistent virus. Treatment
of LCMV persistently infected cells with PF-429242 resulted in rapidelimination of the virus, as assessed by detection of infectious virus
in the cell culture supernatant and viral RNA in cells. Interruption of
drug treatment did not result in re-emergence of virus, indicating
successful extinction. In contrast to acute infection, the addition of
Rib did not enhance the anti-viral effect of PF-429242. A possible ex-
planation for this discrepancy may be much lower expression levels
of GPC in persistent infection, which could be less affected by Rib-
mediated inhibition at the level of viral replication and transcription.
Under our experimental condition, no drug resistant viral escape var-
iants emerged. This observation is in line with previous studies from
our group performed in LCMV persistently infected SKI-1/S1P-deﬁ-
cient cells (Rojek et al., 2010), suggesting that emergence of SKI-1/
S1P-independent LCMV is a rare event. The broad anti-arenaviral ac-
tivity of PF-429242, the synergistic anti-viral effect with Rib, its re-
markable potency in persistent infection, together with the lack of
emerging resistant viral variants, make PF-429242 an attractive
drug candidate. The results of our present study warrant further eval-
uation of PF-429242 in treatment of acute and persistent arenavirus
infection in vivo, which will be investigated in follow-up studies in
suitable small animal models.
Materials and methods
Cells lines and viruses
Human lung epithelial (A549), human embryonic kidney (HEK)
293H, and African green monkey kidney (VeroE6) cells were main-
tained at 37 °C and 5% CO2 in DMEM (Dulbecco's modiﬁed Eagle's me-
dium (Invitrogen)) completed with 10% fetal bovine serum (FCS) and
100 units/ml penicillin and 0.1 mg/ml streptomycin (P/S). Baby ham-
ster kidney cells (BHK-21) were grown in DMEM supplemented with
5% tryptose phosphate broth solution (TPB), 10% FCS and P/S. Chinese
hamster ovary (CHO)K1 cells were grown in DMEM nutrient mixture
F12 Ham (GIBCO BRL, NY) supplemented with 10% FCS and P/S. SRD-
12B cells, CHO knockout (KO) for SKI-1/S1P, and cells under the SKI-
1/S1P inhibitor PF-429242 treatment were supplemented with 5 μg/
ml cholesterol (Sigma, St. Louis, MO), 1 mM sodium mevalonate
(Sigma), and 20 μM sodium oleate (Sigma). Stocks of LCMVwere pre-
pared in BHK-21 cells and titers determined as reported (Dutko and
Oldstone, 1983). JUNV Candid 1 was a kind gift from Dr. Michael
Buchmeier and was produced in VeroE6 cells as described (Rojek et
al., 2008a). Production and titers of retroviral pseudotypes were
done as described earlier (Rojek et al., 2007b; Rojek et al., 2006).
The recombinant viruses have been described elsewhere: rLCMV-
LASVGP (Rojek et al., 2008b), rLCMV-RRRR (Rojek et al., 2010), and
rLCMV-VSVG (Pinschewer et al., 2003).
Antibodies
Monoclonal antibodies (mAbs) 113 (anti-LCMVNP) and 83.6
(anti-LCMVGP) have been described (Buchmeier et al., 1981; Weber
and Buchmeier, 1988), as has mAb SA02-BG12 anti JUNV NP
(Sanchez et al., 1989). Other antibodies included: mAb anti-α-
tubulin (Sigma), rabbit polyclonal anti-Flag (Sigma), rabbit polyclonal
anti-GFP (Chemicon), rhodamine-X-red conjugated anti-mouse IgG,
and Alexa488-conjugated anti-mouse IgG. Anti-mouse IgG and anti-
rabbit IgG conjugated to horseradish peroxidase (HRP) were obtained
from Pierce. Monoclonal antibody to the V5 tag and 4′-6-Diamidino-
2-phenylindole (DAPI) were from Invitrogen.
Cell viability assay
Four times 104 A549 cells/well in a 96-well plate were treated
with the compounds at various concentrations and PBS or DMSO
(2%) as controls. At 48 h post incubation, 100 μl/well of CellTiter-
Glo® luminescent cell viability assay solution (Promega, Dübendorf,
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hold Multimode Platereader TriStar LB 941 model.
Virus infection of cells
Virus inoculums at different MOIs were added to cells and incu-
bated at 37 °C. After 45 min, inoculums were removed, fresh medium
added. When indicated, media were supplemented with lipids and/or
drugs at various concentrations or DMSO/PBS. For LCMV, infected cell
numbers were assessed by IFA using mAb 113 and a secondary anti-
body coupled to rhodamine-X-red (Rojek et al., 2010). Intracellular
FACS staining for LCMV NP was performed as described (Kunz et al.,
2003). Detection of JUNV NP by IFA was performed as reported
(Rojek et al., 2008a). Infection of retroviral pseudotypes was detected
by IF staining for GFP as reported (Rojek et al., 2006).
Pharmacological inhibitors
Ribavirin (1-β-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide)
was purchased from Sigma. Once dissolved in PBS, it was kept at
−80 °C for long term and −20 °C for short term storage. PF-429242
(4-[(diethylamino)methyl]-N-[2-(2-methoxyphenyl)ethyl]-N-[(3R)-
pyrrolidin-3-yl] [benzamide dihydrochloride]), provided by Enamine ,
was dissolved in DMSO at 100 mM and stored at−20 °C.
Transfection
CHOK1, HEK293H or SRD-12B cells were cultured to 90% conﬂu-
ence in 24-well plates (2.5×105 cells/well). Plasmid DNA (800 ng)
was transfected using Lipofectamin2000 (Invitrogen), according to
manufacturer's instructions. Four hours post transfection, medium
was removed and replaced by fresh medium supplemented with
5 μg/ml cholesterol, 1 mM sodium mevalonate, 20 μM sodium oleate
for SRD-12B cells.
Western blot
Cells were lysed with 2× SDS polyacrylamide gel electrophoresis
(PAGE) sample buffer (reducing), and samples separated through
10% SDS-PAGE. Proteins were transferred to nitrocellulose mem-
branes and blocked with 6% (w/v) skim milk in PBS, 0.2% (wt/vol)
Tween-20 (PBST). Blots were incubated with primary antibody over-
night at 4 °C and an appropriate HRP-conjugated secondary antibody
for 1 h at RT. Either enhanced chemo luminescence (ECL) (LiteAblot®,
Euroclone) or ECL AdvanceTM western blotting detection Kit (GE
Healthcare) was used for revelation.
Induction of SREBP2 and ATF6 cleavage
To induce upregulation of genes downstream of SREPB, CHOK1
cells were treated with Ham's F-12 DMEM 1:1, 5% LPDS, 50 μM sodi-
um mevalonate, 50 μM mevastatin for 18 h as described (Pullikotil
et al., 2004). To induce upregulation of genes downstream of ATF6,
cells were treated with tunicamycin (5 μg/ml) for 4 h (Pasqual et al.,
2011). Fourteen hours after the induction of SREPB cleavage and si-
multaneously with tunicamycin treatment, PF-429242(10 μM) or
DMSO (2%) was added to the cells. Four hours post treatment cells
were washed twice with PBS and total RNA was isolated to perform
RT-qPCR analyses.
Real-time quantitative PCR (RT-qPCR)
Total RNAwas isolated using RNeasyMini Kit (Qiagen, Chatsworth,
CA). The lysatewas homogenizedwith a Qiashredder kit (Qiagen). The
RT reactionwas performed using QuantiTect Reverse Transcription Kit
by Qiagenwith 1 μg of template RNA. PCRwas donewith SYBR® greenReagents (Applied Biosystems, Foster City, CA). Speciﬁc primers were
used to determine the level of expression of HMGCS1 (5′-GCCCTTGA-
GATCTACTTTCC-3′, 5′-CCAGGCCAATGGTATACTTC-3′), HSPA5 (5′-
CACTTGGAATGACCCTTCAG-3′, 5′-GTTTGCCCACCTCCAATATC-3′) and
HMBS (5′-AGATTCTTGATACTGCACTC-3′, 5′-GAAAGACAACAGCATCA-
CAA-3′) (Microsynth, Balgach, Switzerland). Real-time PCR analyses
were performed in triplicate (real-time PCR ABI PRISM 7000 se-
quence detection system Applied Biosystems). The RT-qPCR on
LCMV NP was performed with speciﬁc primers (5′-GAGCCTTGA-
CAGCTTAGAAC-3′, 5′-CTTGCCGACCTCTTCAATG-3′) and a TaqMan
probe (5′-CCTGCGGAAGAGCAC-3′), the TaqMan probe (GAPDH;
Hs99999905_m1) (Applied Biosystems) was used as calibrator. RNA
extraction, reverse transcriptase and qPCR were performed by the di-
agnostic facility of the Institute of Microbiology in Lausanne. The RNA
was extracted using MagNA Pure 96 DNA and Viral NA Small Volume
Kit (Roche) using GeneAmp ® PCR System 9700 (Applied biosystem).
The RT reaction was performed with the High Capacity cDNA Reverse
Transcription Kit (Applied biosystem) using GeneAmp ® PCR System
9700 (Applied biosystem). Finely the qPCR plate was prepared with
Freedom EVO 150 Tecan® and the qPCR run with 7900HT Sequence
Detection System (Applied biosystem). Results were analyzed using
the program SDS 2.2. The analytical sensitivity of the RT-qPCR for
LCMV NP was determined using an expression plasmid pCAGGS con-
taining the cDNA LCMV NP (ARM53b) in 10-fold serial dilutions. The
experiment showed a linear range between 50 and 5×104 copies and
a limit of detection of ≤50 copies per reaction.
For the ampliﬁcation of the GPC open reading frame from cellular
RNA we used QuantiTect Reverse Transcription Kit (Qiagen) with
600 ng of template RNA. A PCR using speciﬁc GPC primers (5′-GCC
AGT GTA GAA CCT TCA GAG-3′, 5′ CCC GGA TCC TCA GCG TCT TTT
CCA GAC GGT TTT TAC ACC3′’) yielded a 1000 bp PCR including the
SKI-1/S1P site. PCR products were run on a 1% agarose gel. PCR prod-
ucts were sequenced and no mutations were found for the GPC cleav-
age site of the sample obtained at 4 days after the end of PF-429242
treatment.
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